- Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
- Macro Biologics, Inc. develops large molecule biologics which can alleviate or improve skin
issues and prevent wound infections - Beiersdorf also joins Macro Biologics, Inc. as an investor through its Oscar & Paul Corporate
Venture Capital Unit
Hamburg, September 4, 2024 – Beiersdorf and Macro Biologics, Inc. have entered into a multi-year partnership: Together, they aim to develop biodegradable antimicrobial peptides with broad applications in skincare and wound care. At the same time, the skincare company is investing in Macro Biologics through its Oscar & Paul Corporate Venture Capital Unit. By doing so, Beiersdorf brings Macro Biologics’ cutting-edge technology in antimicrobial research into the world of skincare and wound care – highlighting its commitment to continuously offering revolutionary and sustainable innovations to its consumers.
This collaboration in a dynamic field of research will focus on using Macro Biologics’ highly effective antimicrobial peptides, called “Amicidine,” in Beiersdorf’s innovative product and formula development. Amicidine is effective against a wide range of bacteria, which can help reduce skin irritations or improve skin appearance. Additionally, it is designed for early local application to prevent wound infections. The shared goal of the two companies is to create highly effective, safe, and sustainable solutions for a variety of applications across Beiersdorf’s brand portfolio, especially in dermatological skincare and wound care.
“By collaborating with Macro Biologics, we are strengthening Beiersdorf’s innovation capabilities and our leadership in Climate Care in line with our ‘Win with Care’ strategy,” emphasizes Dr. Gitta Neufang, Corporate Senior Vice President Global R&D at Beiersdorf. “With Macro Biologics, we have found an outstanding partner in the promising field of antimicrobial peptides, one who shares our visionary commitment to innovation. We are very excited to bring this cutting-edge technology together into the world of skincare and wound care.”
“We are thrilled with the partnership with Beiersdorf, a global heavyweight in the fields of skincare and wound care,” said Dr. Michael Bevilacqua, CEO and CSO of Macro Biologics. “For us, this collaboration is a perfect fit – from both a research and business perspective. Beiersdorf’s comprehensive expertise in developing and marketing products will be essential in ensuring that Amicidine can improve people’s lives in many ways. And this partnership is built on shared principles: We both strive to create sustainable value – for people and the environment.”
